PLA2R1 and membranous glomerulonephritis: This limitation is particularly relevant in the retrospective cohort, where it is challenging to determine whether the risk of posttransplant recurrence is attributable to pretransplant anti-PLA2R1 antibody positivity or to the etiology of anti-PLA2R1-associated membranous nephropathy compared to other etiologies.